ATE479667T1 - Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis - Google Patents

Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis

Info

Publication number
ATE479667T1
ATE479667T1 AT04709122T AT04709122T ATE479667T1 AT E479667 T1 ATE479667 T1 AT E479667T1 AT 04709122 T AT04709122 T AT 04709122T AT 04709122 T AT04709122 T AT 04709122T AT E479667 T1 ATE479667 T1 AT E479667T1
Authority
AT
Austria
Prior art keywords
sup
thiazolyl
based compounds
kinase inhibitors
kinase
Prior art date
Application number
AT04709122T
Other languages
English (en)
Inventor
John Hynes
Hong Wu
Katerina Leftheris
Chunjian Liu
Jagabandhu Das
Robert Moquin
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE479667T1 publication Critical patent/ATE479667T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT04709122T 2003-02-06 2004-02-06 Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis ATE479667T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44541003P 2003-02-06 2003-02-06
PCT/US2004/003879 WO2004071440A2 (en) 2003-02-06 2004-02-06 Thiazolyl-based compounds useful as kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE479667T1 true ATE479667T1 (de) 2010-09-15

Family

ID=32869361

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04709122T ATE479667T1 (de) 2003-02-06 2004-02-06 Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis

Country Status (6)

Country Link
US (2) US7169771B2 (de)
EP (1) EP1594854B1 (de)
AT (1) ATE479667T1 (de)
DE (1) DE602004028907D1 (de)
ES (1) ES2349532T3 (de)
WO (1) WO2004071440A2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2515215A1 (en) * 2003-02-10 2004-08-26 Amgen Inc. Vanilloid receptor ligands and their use in treatments
AU2004236240C1 (en) 2003-05-01 2010-11-04 Bristol-Myers Squibb Company Aryl-substituted pyrazole compounds useful as kinase inhibitors
GB0329572D0 (en) 2003-12-20 2004-01-28 Astrazeneca Ab Amide derivatives
US20050215795A1 (en) * 2004-02-06 2005-09-29 Bang-Chi Chen Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
US7652146B2 (en) 2004-02-06 2010-01-26 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
US7491725B2 (en) * 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
TWI338004B (en) * 2004-02-06 2011-03-01 Bristol Myers Squibb Co Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
TW200628156A (en) * 2004-11-04 2006-08-16 Bristol Myers Squibb Co Combination of a SRC kinase inhibitor and a BCR-ABL inhibitor for the treatment of proliferative diseases
US20080125432A1 (en) * 2004-12-01 2008-05-29 Devgen Nv 5-Carboxamido Substituted Thiazole Derivatives that Interact With Ion Channels, In Particular With Ion Channels From the Kv Family
CN101106990B (zh) * 2005-01-26 2010-12-08 Irm责任有限公司 用作蛋白激酶抑制剂的化合物和组合物
US20060178388A1 (en) 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
KR101142283B1 (ko) * 2005-03-11 2012-05-07 스미또모 가가꾸 가부시끼가이샤 2-아미노티아졸 카르복사미드 유도체의 신규한 제조방법
EP1911751A4 (de) 2005-06-21 2010-10-20 Mitsui Chemicals Agro Inc Amidderivat und pestizid, das eine solche verbindung enthält
WO2007138110A2 (en) * 2006-06-01 2007-12-06 Devgen N.V. Compounds that interact with ion channels, in particular with ion channels from the kv family
EP2104671A2 (de) * 2006-09-25 2009-09-30 Mutabilis SA Substituierte heterocyclyl-carbonyl-amino-essigsäure-derivate als hemmer der synthese bakterieller heptosen, verfahren zu ihrer herstellung und biologische anwendungen für besagte hemmer
WO2008057775A2 (en) * 2006-10-27 2008-05-15 Bristol-Myers Squibb Company Heterocyclic amide compounds useful as kinase inhibitors
JP5225288B2 (ja) * 2006-12-20 2013-07-03 ブリストル−マイヤーズ スクイブ カンパニー キナーゼ阻害剤として有用なチアゾリル化合物
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
US8304547B2 (en) 2007-10-24 2012-11-06 Astellas Pharma Inc. Azolecarboxamide compound or salt thereof
WO2009132310A1 (en) * 2008-04-25 2009-10-29 Wisconsin Alumni Research Foundation Inhibitors of udp-galactopyranose mutase thwart mycobacterial growth
WO2010144909A1 (en) 2009-06-12 2010-12-16 Novartis Ag Fused heterocyclic compounds and their uses
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
CA2856291C (en) 2011-11-17 2020-08-11 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
RU2495430C1 (ru) * 2012-03-29 2013-10-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Астраханская государственная академия" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО АГМА Минздравсоцразвития России) Способ оценки эффективности терапии хронического миелолейкоза
RU2495427C1 (ru) * 2012-07-04 2013-10-10 Федеральное бюджетное учреждение науки "Уфимский научно-исследовательский институт медицины труда и экологии человека" Способ прогнозирования ответа на химиотерапию при хроническом лимфолейкозе
EP2909194A1 (de) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Hemmer der cyclinabhängigen kinase 7 (cdk7)
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
US10047070B2 (en) 2013-10-18 2018-08-14 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
AU2014337122B2 (en) 2013-10-18 2019-01-03 Dana-Farber Cancer Institute, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
EP3236959B1 (de) 2014-12-23 2025-09-24 Dana-Farber Cancer Institute, Inc. Hemmer der cyclinabhängigen kinase 7 (cdk7)
AU2016243529B2 (en) 2015-03-27 2021-03-25 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
EP4019515A1 (de) 2015-09-09 2022-06-29 Dana-Farber Cancer Institute, Inc. Hemmer von cyclinabhängigen kinasen
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
US10080757B2 (en) 2016-03-11 2018-09-25 Wisconsin Alumni Research Foundation Inhibitors of UDP-galactopyranose mutase
UA126099C2 (uk) 2018-05-09 2022-08-10 ЕлДжи КЕМ, ЛТД. Сполука, яка виявляє інгібувальну активність відносно ентеропептидази
AU2019285066B2 (en) 2018-06-15 2024-06-13 Handa Pharmaceuticals, Inc. Kinase inhibitor salts and compositions thereof
JP7590185B2 (ja) 2018-06-25 2024-11-26 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
AU2019413694B2 (en) 2018-12-28 2025-03-20 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
US12384773B2 (en) 2023-11-02 2025-08-12 Arcus Biosciences, Inc. Thiazole compounds and methods of use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6262096B1 (en) 1997-11-12 2001-07-17 Bristol-Myers Squibb Company Aminothiazole inhibitors of cyclin dependent kinases
SI0928790T1 (en) * 1998-01-02 2003-06-30 F. Hoffmann-La Roche Ag Thiazole derivatives
JP2002531549A (ja) 1998-12-04 2002-09-24 ブリストル−マイヤーズ スクイブ カンパニー カリウムチャネル・モジュレーターとしての３−置換−４−アリールキノリン−２−オン誘導体
SK287200B6 (sk) 1999-02-22 2010-03-08 Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf) C-21 modifikované epotilóny, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a použitie
US6548529B1 (en) 1999-04-05 2003-04-15 Bristol-Myers Squibb Company Heterocyclic containing biphenyl aP2 inhibitors and method
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
PT1169038E (pt) 1999-04-15 2012-10-26 Bristol Myers Squibb Co Inibidores cíclicos da proteína tirosina cinase
CA2381215A1 (en) 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. P38map kinase inhibitors
SE9904177D0 (sv) 1999-11-18 1999-11-18 Astra Ab Novel compounds
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
MY138097A (en) 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
EP1268474A2 (de) * 2000-03-30 2003-01-02 Takeda Chemical Industries, Ltd. Substituierte 1,3-thiazol-verbindungen, ihre herstellung und verwendung
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
JP4523271B2 (ja) 2001-06-01 2010-08-11 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼのインヒビターとして有用なチアゾール化合物
HN2002000156A (es) * 2001-07-06 2003-11-27 Inc Agouron Pharmaceuticals Derivados de benzamida tiazol y composiciones farmaceuticas para inhibir la proliferacion de celulas y metodos para su utilización.
SK1102004A3 (sk) 2001-08-31 2005-05-05 Bristol-Myers Squibb Company Liečivo na liečenie proliferačných ochorení a farmaceutická kompozícia na liečenie rakoviny
AU2002357137A1 (en) 2001-12-10 2003-06-23 Bristol-Myers Squibb Company (1-phenyl-2-heteroaryl)ethyl-guanidine compounds as inhibitors of mitochondrial f1f0 atp hydrolase

Also Published As

Publication number Publication date
US20070093537A1 (en) 2007-04-26
ES2349532T3 (es) 2011-01-04
EP1594854A2 (de) 2005-11-16
DE602004028907D1 (de) 2010-10-14
US7323482B2 (en) 2008-01-29
EP1594854B1 (de) 2010-09-01
EP1594854A4 (de) 2007-07-18
US20040220233A1 (en) 2004-11-04
WO2004071440A2 (en) 2004-08-26
US7169771B2 (en) 2007-01-30
WO2004071440A3 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
ATE479667T1 (de) Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis
ATE482200T1 (de) Als kinaseinhibitoren geeignete arylsubstituierte pyrazolamidverbindungen
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
GB0129476D0 (en) Organic compounds
WO2007016392A3 (en) Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
NO20062267L (no) Hepatitt C virus inhibitorer
DK1070056T3 (da) Phthalazinon-PDE III/IV-inhibitorer
NO20062339L (no) Hepatitt C virus-inhibitoerer
WO2005092858A3 (en) Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
GEP20074148B (en) Pyrrolo-triazine aniline compounds useful as kinase inhibitors
CA2423103A1 (en) N-acylsulfonamide apoptosis promoters
MXPA05012837A (es) Inhibidores de caspasa y usos de los mismos.
ATE399168T1 (de) Imidazopyridin-derivate und ihre verwendung als induzierbare no-synthase inhibitoren
DE602005025332D1 (de) 4-ä2-(cycloalkylamino)pyrimidin-4-ylü-(phenyl)imidazolin-2-onderivate als inhibitoren der p38-map-kinase zur behandlung von entzündlichen krankheiten
DE602004005881D1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
DE60314381D1 (de) Benzylimidazolyl substituierte 2-chinolon und chinazolinon derivate zur verwendung als farnesyl transferase inhibitoren
ATE543803T1 (de) 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
HRP20050082A2 (en) 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
MEP12108A (en) Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them
BR0308935A (pt) Inibidor de fosfodiesterase iv contendo derivado de piridilacrilamida
EA200300458A1 (ru) Новые соединения аминотриазолона, способ их получения и фармацевтические композиции, содержащие их
DE502004009016D1 (de) Verwendung von chinaldin-und naphthalinderivaten als kristallisationsmodifikatoren
ATE449773T1 (de) Homomorpholinoxazolidinone als antibakterielle mittel
ATE449760T1 (de) Nichtpeptidinhibitoren von matrixmetalloproteinasen
TW200602046A (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties